FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Elon Musk Announces Terafab: SpaceX and Tesla to Build Dual AI Chip Factories in Austin, Texas 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
9 Tips for Avoiding Tax Season Cyber Scams 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Sanofi (EPA: SASY) has announced encouraging late-stage clinical trial results for its investigational drug amlitelimab, reinforcing its potential as a new treatment option for patients with moderate to severe eczema. The French pharmaceutical giant revealed that the drug met key endpoints in two Phase 3 studies, demonstrating significant efficacy and a favorable safety profile in patients aged 12 years and older.
Amlitelimab was evaluated in individuals suffering from moderate to severe atopic dermatitis, a chronic inflammatory skin disease commonly known as eczema. This condition is marked by persistent itching, redness, dryness, and skin inflammation, often having a major impact on quality of life. According to Sanofi, patients treated with amlitelimab experienced meaningful improvements in disease severity and symptoms compared with baseline measurements.
The two late-phase studies assessed the drug’s performance over a 24-week treatment period. Participants received amlitelimab either once every four weeks or once every 12 weeks, allowing researchers to evaluate both dosing schedules. Results showed consistent benefits across both regimens, highlighting the drug’s flexibility and potential convenience for long-term management of eczema.
Importantly, Sanofi noted that amlitelimab was well-tolerated throughout the trials. The safety data aligned with findings from earlier studies, with no unexpected adverse effects reported. This consistent safety profile strengthens confidence in the drug’s suitability for broader patient populations, including adolescents and adults with chronic eczema.
Based on these positive Phase 3 outcomes, Sanofi plans to proceed with global regulatory submissions for amlitelimab. The company aims to seek approval from major health authorities, potentially paving the way for the drug’s commercial launch. If approved, amlitelimab could expand Sanofi’s dermatology portfolio and offer a new biologic treatment option for patients who have limited responses to existing therapies.
The announcement underscores Sanofi’s continued focus on innovation in immunology and dermatology, while positioning amlitelimab as a promising candidate in the competitive eczema treatment market.
